UBR5-mediated degradation of MOAP-1 and MOIP-1 confers cisplatin resistance in ovarian cancer, illustrating the capacity for UBR5 to enhance cancer cell survival following chemotherapy [60]. This evidence concerns the gene UBR5 and ovarian carcinoma.